RSLV-132

DRUG5 trials

Sponsors

Resolve Therapeutics

Conditions

Post-acute Corona Virus 19 (COVID-19) (Long COVID)Primary Sjögren SyndromeSjogren's SyndromeSystemic Lupus Erythematosus

Phase 1

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

CompletedNCT02194400

Resolve TherapeuticsSystemic Lupus Erythematosus

Start: 2014-07-31End: 2015-11-30Updated: 2015-12-09

Phase 2

A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)

CompletedNCT02660944

Resolve TherapeuticsSystemic Lupus Erythematosus

Start: 2016-01-03End: 2020-08-10Updated: 2021-03-10

A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome

CompletedNCT03247686

Resolve TherapeuticsSjogren's Syndrome

Start: 2017-02-01End: 2019-08-01Updated: 2021-04-02

Phase 2 Study of RSLV-132 in Subjects With Long COVID

CompletedNCT04944121

Resolve TherapeuticsPost-acute Corona Virus 19 (COVID-19) (Long COVID)

Start: 2021-06-25End: 2023-11-30Updated: 2024-05-29

A Study of RSLV-132 in Females With Sjögren's Disease

RecruitingNCT06440525

Resolve TherapeuticsPrimary Sjögren Syndrome

Start: 2024-12-01End: 2027-03-01Target: 106Updated: 2025-07-18

Related Papers

STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol

PLoS ONE2023-02-1529 citations